| Name |
|---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
Lyra Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of anti-inflammatory therapies for the localized treatment of patients with chronic rhinosinusitis, or CRS. Its products include LYR-210...
Benzinga Rankings give you vital metrics on any stock – anytime.
You can purchase shares of LYRA THERAPEUTICS INC by Lyra Therapeutics, Inc. (OTCEM:LYRA) through any online brokerage.
There are no as such competitors for LYRA THERAPEUTICS INC by Lyra Therapeutics, Inc..
LYRA THERAPEUTICS INC by Lyra Therapeutics, Inc. has a consensus price target of $197.00.
The stock price for LYRA THERAPEUTICS INC by Lyra Therapeutics, Inc. (OTCEM: LYRA) is $0.19 last updated October 9, 2026 at 2:33 PM EDT.
There are no upcoming dividends for LYRA THERAPEUTICS INC by Lyra Therapeutics, Inc..
LYRA THERAPEUTICS INC by Lyra Therapeutics, Inc. does not have any upcoming earnings scheduled.
There is no upcoming split for LYRA THERAPEUTICS INC by Lyra Therapeutics, Inc..
LYRA THERAPEUTICS INC by Lyra Therapeutics, Inc. is in the Health Care sector and Pharmaceuticals industry. They are listed on the OTCEM.
